Version history

{
  "session_id": "sess_SDA-2026-04-14-gap-pubmed-20260410-193244-89904941_20260416-035819",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: APOE4-Driven Cholesterol Dysregulation in Oligodendrocytes\n\n## 1. Hypotheses with Highest Translational Potential\n\n### Tier 1: **Cholesterol Efflux Enhancement via ABCA1/ABCG1 Activation**\n\nThis approach has the strongest translational alignment with existing druggable targets. Rather than inhibiting SREBP2 (which risks disrupting compensatory biosynthetic pathways), enhancing downstream cholesterol efflux channels the system toward restoration of myelin lipid homeostasis. Critically, this avoids the liver toxicity that derailed first-generation LXR agonists by targeting oligodendrocyte-selective pathways.\n\n### Tier 2: **ApoE4-Structural Stabilization or Isoform-Specific Chaperone Therapy**\n\nThis addresses the root cause if ApoE4 destabilization is confirmed as the primary upstream event. Structural stabilization would prevent proteasomal degradation, restore physiological ApoE levels, and re-establish normal LXRβ feedback. The challenge is developing CNS-penetrant small molecules with isoform specificity.\n\n### Tier 3: **SREBP2-Attenuated Function in Oligodendrocytes (via Cleavage Inhibitors or SCAP Modulators)**\n\nDespite the Skeptic's valid concerns, SREBP2 remains an attractive target if temporal dynamics can be established. A therapeutic window may exist where modest SREBP2 reduction corrects dysregulation without impairing baseline myelination.\n\n---\n\n## 2. Clinical Evidence, Safety, and Patient Population Fit\n\n| Hypothesis | Current Clinical Evidence | Safety Considerations | Patient Population Fit |\n|-----------|--------------------------",
  "tokens_used": "399"
}